Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DCVAC/OvCa

Next Previous
Drug Profile

DCVAC/OvCa

Alternative Names: Dendritic cell vaccine/Ovarian cancer - Sotio

Latest Information Update: 03 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SOTIO
  • Developer Peking University; SOTIO
  • Class Antineoplastics; Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 31 Aug 2021 SOTIO withdraws the phase III VITALIA trial in Fallopian tube cancer, Peritoneal cancer and relapsed Ovarian cancer (Late-stage disease)
  • 04 Jun 2021 Updated efficacy and safety data from the phase II SOV01 trial in Ovarian cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
  • 23 Mar 2021 Phase-II clinical trials in Fallopian tube cancer (First-line therapy, Late-stage disease, Adjuvant therapy) in China (SC) (NCT04834544)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top